The EU Commission acknowledges commitments offered by Danish pharmaceutical company in a case of abuse of dominant position in the market for insulin (Novo Nordisk)

"Novo Nordisk"* Undertakings have been accepted from Novo Nordisk, the Danish pharmaceutical company, which are designed to ensure competition in the markets for components of Novo Nordisk‘s insulin self-injection delivery systems. Novo Nordisk is Europe’s leading insulin producer. In 1985 Novo Nordisk introduced a new method of insulin self-injection, the so-called “insulin pen” system. For many diabetes sufferers, this has proved more convenient than traditional self-injection delivery systems such as the hypodermic syringe. About a third of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • DG COMP (Brussels)
  • DG COMP (Brussels)

Quotation

Joos Stragier, Hugo Verlackt, The EU Commission acknowledges commitments offered by Danish pharmaceutical company in a case of abuse of dominant position in the market for insulin (Novo Nordisk), 1 January 1996, e-Competitions Bulletin January 1996, Art. N° 39563

Visites 299

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues